Acute Promyelocytic Leukemia: Clinical Relevance of Two Major PML-RARα Isoforms and Detection of Minimal Residual Disease by Retrotranscriptase/Polymerase Chain Reaction to Predict Relapse

Recent data have shown that the PML-RARα fusion gene resulting from translocation t(15; 17) is a highly reliable molecular marker of acute promyelocytic leukemia (APL). In this study performed on 97 Chinese patients with APL, the retrotranscriptase/polymerase chain reaction (RT/PCR) was used to evaluate the clinical relevance of the long (L) or short (S) PML-RARα fusion mRNA isoforms and to study minimal residual disease during clinical remission (CR). There were more early deaths during the all-transretinoic acid (ATRA) induction treatment and more relapses within 2 years of CR in the S-type (6 of 19 cases) than in the L-type group (2 of 33 cases) (P< .025). Among 12 cases analyzed before and after the ATRA-induced CR, 9 cases (75%) showed positive RT/PCR, whereas only 3 cases showed a negative result, justifying the need for chemotherapy after ATRA-induced CR. Eleven of 62 APL patients in CR, after ATRA-induced CR and chemotherapy consolidation (follow-up, from 3 to 72 months), showed positive RT/PCR. Five of them relapsed within 1 to 6 months after the positive test; one converted to negative after further chemotherapy; and 5 remained in CR status without further PCR data. However, the latter 5 cases all received further intensive consolidation therapy after the PCR posi-tivity. These results show that a positive RT/PCR of PML-RARα is a sensitive predictor of relapse in APL.